Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALNY
  • CUSIP: 02043Q10
Key Metrics:
  • Previous Close: $70.83
  • 50 Day Moving Average: $69.27
  • 200 Day Moving Average: $63.87
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.39
  • P/E Growth: -0.34
  • Market Cap: $5.84B
  • Outstanding Shares: 85,724,000
  • Beta: 2.53
Additional Links:
Companies Related to Alnylam Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (?)
Ratings Breakdown: 2 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.85)
Consensus Price Target: $116.00 (63.77% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateFirmActionRatingPrice TargetDetails
8/10/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$63.00 -> $65.00View Rating Details
8/7/2016Cowen and CompanyReiterated RatingBuy$150.00View Rating Details
8/5/2016Needham & Company LLCReiterated RatingBuy$152.00View Rating Details
8/5/2016JPMorgan Chase & Co.Boost Price TargetOverweight$80.00 -> $83.00View Rating Details
8/5/2016Jefferies GroupBoost Price TargetBuy$80.00 -> $86.00View Rating Details
8/2/2016Morgan StanleyInitiated CoverageOverweight$93.00View Rating Details
7/19/2016Leerink SwannReiterated RatingBuyView Rating Details
7/17/2016FBR & CoReiterated RatingOutperform$180.00View Rating Details
7/11/2016Chardan CapitalReiterated RatingBuyView Rating Details
7/10/2016JMP SecuritiesReiterated RatingBuyView Rating Details
6/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
5/26/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldView Rating Details
6/24/2015Deutsche Bank AGSet Price TargetBuy$155.00View Rating Details
6/24/2015Canaccord GenuityReiterated RatingBuy$160.00View Rating Details
3/17/2015Janney Montgomery ScottInitiated CoverageBuy$139.00View Rating Details
3/3/2015Barclays PLCInitiated CoverageOverweight$125.00View Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.66)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.60)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.56)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.54)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Current Year EPS Consensus Estimate: $-4.7 EPS
Next Year EPS Consensus Estimate: $-5.29 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.14)($1.08)($1.11)
Q2 20164($1.32)($1.19)($1.26)
Q3 20164($1.35)($1.25)($1.30)
Q4 20164($1.41)($0.96)($1.26)
(Data provided by Zacks Investment Research)


Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
News IconHow is the Crowd Rating Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)? - Post News (NASDAQ:ALNY) - August 24 at 3:27 PM logoETF’s with exposure to Alnylam Pharmaceuticals, Inc. : August 24, 2016 (NASDAQ:ALNY) - August 24 at 3:27 PM
News IconAmyloid-related heart failure now detectable with imaging test (NASDAQ:ALNY) - August 24 at 11:42 AM logoAlnylam Pharmaceuticals Has Returned 24.1% Since SmarTrend Recommendation (ALNY) (NASDAQ:ALNY) - August 24 at 11:42 AM
News IconStock Trading Above Moving Averages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post News (NASDAQ:ALNY) - August 22 at 8:35 PM logoCan Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Keep Up With Analyst Expectations? - Investor Newswire (NASDAQ:ALNY) - August 22 at 3:28 PM
News IconStock Gaining Over the Past Six Months: Alnylam Pharmaceuticals ... - Post News (NASDAQ:ALNY) - August 21 at 3:24 PM
News IconSell-side Price Target Review on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post News (NASDAQ:ALNY) - August 21 at 8:12 AM
News IconShares Holding Above Moving Averages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post News (NASDAQ:ALNY) - August 20 at 8:25 AM logoAnalysts See Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ... - (NASDAQ:ALNY) - August 18 at 3:33 PM
News IconCrowd Perspectives & Analyst Views on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)? - Post News (NASDAQ:ALNY) - August 17 at 3:28 PM logoUptrend Call Working As Alnylam Pharmaceuticals Stock Rises 21.8% (ALNY) (NASDAQ:ALNY) - August 16 at 3:27 PM logoAlnylam Pharmaceuticals, Inc. Cranks Out the Data - Motley Fool (NASDAQ:ALNY) - August 13 at 3:25 PM
News IconAlnylam Pharmaceuticals, Inc. Cranks Out the Data - (NASDAQ:ALNY) - August 13 at 11:36 AM logoALNY: Insiders vs. Shorts (NASDAQ:ALNY) - August 12 at 8:55 PM logoAlnylam Pharmaceuticals, Inc. Cranks Out the Data (NASDAQ:ALNY) - August 12 at 5:01 PM logoALNYLAM PHARMACEUTICALS, INC. Financials (NASDAQ:ALNY) - August 11 at 3:28 PM logoAlnylam Pharma To Present At Canaccord Genuity Conference; Webcast At 11:00 AM (NASDAQ:ALNY) - August 10 at 10:46 AM logoAlnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue? (NASDAQ:ALNY) - August 10 at 10:46 AM logoETF’s with exposure to Alnylam Pharmaceuticals, Inc. : August 9, 2016 (NASDAQ:ALNY) - August 9 at 4:30 PM
News IconProprotein Convertase Subtilisin/Kexin Type 9 – Pipeline Review, H1 2016 – New Market Report (NASDAQ:ALNY) - August 9 at 12:11 PM logoAlnylam Pharma (ALNY) Announces Completion of ENDEAVOUR Phase 3 Enrollment (NASDAQ:ALNY) - August 8 at 8:54 PM logoAlnylam Pharma (ALNY) Announces Completion of ENDEAVOUR Phase 3 Enrollment - (NASDAQ:ALNY) - August 8 at 3:29 PM logoAlnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:ALNY) - August 8 at 3:29 PM logoAlnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an ... (NASDAQ:ALNY) - August 8 at 8:14 AM logoAlnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM) (NASDAQ:ALNY) - August 8 at 8:14 AM logoEdited Transcript of ALNY earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:ALNY) - August 5 at 8:50 PM logoEARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q2 Earnings Report (NASDAQ:ALNY) - August 5 at 3:27 PM logoBRIEF-Alnylam Pharmaceuticals Q2 GAAP loss per share $1.05 (NASDAQ:ALNY) - August 5 at 3:27 PM logoAlnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress (NASDAQ:ALNY) - August 5 at 3:27 PM logoBRIEF-Alnylam Pharmaceuticals Q2 GAAP loss per share $1.05 - Reuters (NASDAQ:ALNY) - August 4 at 9:10 PM logoAlnylam reports 2Q loss (NASDAQ:ALNY) - August 4 at 9:10 PM logoEarnings Reaction History: Alnylam Pharmaceuticals Inc., 50.0% Follow-Through Indicator, 6.1% Sensitive - Nasdaq (NASDAQ:ALNY) - August 4 at 3:29 PM logoWhy Alnylam Pharmaceuticals, Inc. Stock Gained 10.8% in July - Motley Fool (NASDAQ:ALNY) - August 4 at 3:29 PM logoAlnylam Pharmaceuticals Inc Earnings Call (Q2 2016) (NASDAQ:ALNY) - August 4 at 11:57 AM logoDrug Delivery Infusion Systems - Medical Devices Pipeline Assessment, 2016: New Research Report Available (NASDAQ:ALNY) - August 3 at 11:59 AM logoAlnylam Pharma's Pipeline Offers Plenty Upside Potential (NASDAQ:ALNY) - August 3 at 11:59 AM logoAlnylam to Webcast Presentation at Canaccord Genuity Growth Conference (NASDAQ:ALNY) - August 2 at 9:02 PM logoAlnylam Pharma's Pipeline Offers Plenty Upside Potential - Benzinga (NASDAQ:ALNY) - August 2 at 3:26 PM logoCoverage initiated on Alnylam Pharma by Morgan Stanley (NASDAQ:ALNY) - August 2 at 3:26 PM logoNotable Stocks within Analysts Radar: Insulet Corporation (NASDAQ ... - Street Updates (NASDAQ:ALNY) - August 1 at 3:26 PM logoBioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors (NASDAQ:ALNY) - August 1 at 8:13 AM
News IconTransthyretin (ATTR or Prealbumin or TBPA or TTR) Pipeline Review –By Alnylam Pharmaceuticals, Inc,Arcturus Therapeutics, Inc 2016 (NASDAQ:ALNY) - July 31 at 8:21 AM logoAlnylam Pharmaceuticals Inc.: Alnylam to Webcast Conference Call ... - The Wall Street Transcript (NASDAQ:ALNY) - July 29 at 3:27 PM logoEditas Medicine Appoints Akshay Vaishnaw, M.D., Ph.D., to its Board of Directors (NASDAQ:ALNY) - July 29 at 10:49 AM logoAlnylam Pharmaceuticals Inc.: Alnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results (NASDAQ:ALNY) - July 28 at 10:05 PM logoAlnylam Pharmaceuticals : to Webcast Conference Call Discussing Second Quarter 2016 Financial Results (NASDAQ:ALNY) - July 28 at 4:27 PM logoAlnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results (NASDAQ:ALNY) - July 28 at 4:08 PM logoAlnylam Pharmaceuticals Inc.: Alnylam Announces New Positive Interim Phase 1 ... (NASDAQ:ALNY) - July 27 at 12:03 PM logoGlobal RNA Based Therapeutics Market Analysis, Statistics, Industry Review and Forecasts to 2020 (NASDAQ:ALNY) - July 26 at 9:30 PM


Alnylam Pharmaceuticals (NASDAQ:ALNY) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff